Anavex announced the publication of a peer-reviewed study in Neuroscience Letters, showing that pre-treatment with blarcamesine prevented amyloid-beta–induced memory impairment and oxidative brain injury in an Alzheimer’s disease animal model, according to the company. The research demonstrated significant protection against learning and memory deficits and reduced vulnerability to amyloid-induced oxidative stress.
The company said that the findings align with previously established mechanisms in which blarcamesine activates SIGMAR1 to enhance autophagic flux, restore proteostasis, and regulate amyloid precursor protein processing. Activation of SIGMAR1 is described as a potential therapeutic approach in neurodegenerative disorders due to its role in promoting neurogenesis, reducing neuroinflammation, mitigating oxidative stress, and maintaining cellular homeostasis.
Anavex claims the study reinforces blarcamesine’s potential as a preventive pharmacologic agent and supports further clinical investigation. The publication marks a new preclinical milestone, underscoring the compound’s capacity to act upstream of both amyloid and tau pathologies. This advance may help inform future clinical trial design and development strategy.
